Associated Papers
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
He C et al.
Current Treatment Options in Oncology, 2024
Diagnosis, Treatment, and Prognosis of Patients with Primary Familial Gastrointestinal Stromal Tumor: A Case Report and Literature Review.
Yan M et al.
The Oncologist, 2023
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
Hadad S et al.
Acta Neuropathologica, 2023
Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas.
Bedics G et al.
Scientific Reports, 2023
A Rare PDGFRA Exon 15 Germline Mutation Identified in a Patient With Phenotypic Manifestations Concerning for GIST-Plus Syndrome: A Case Report and Review of Literature.
Wang C et al.
International Journal of Surgical Pathology, 2023
Protocol optimization of a targeted sequencing panel for genomic profiling of bronchoalveolar lavage fluid in lung cancer.
Sather CL et al.
Cancer Medicine, 2023
Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.
Masucci MT et al.
International Journal of Molecular Sciences, 2023
Cooperativity between H3.3K27M and PDGFRA poses multiple therapeutic vulnerabilities in human iPSC-derived diffuse midline glioma avatars.
Skinner KR et al.
Biorxiv : the Preprint Server for Biology, 2023
Enhancing oral squamous cell carcinoma prediction: the prognostic power of the worst pattern of invasion and the limited impact of molecular resection margins.
Hurník P et al.
Frontiers in Oncology, 2023
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.
Wong NACS et al.
Cancer Genetics, 2022
Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice.
Steeghs EMP et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021
PDGF receptor mutations in human diseases.
Guérit E et al.
Cellular and Molecular Life Sciences : Cmls, 2021
Update on Molecular Genetics of Gastrointestinal Stromal Tumors.
Brčić I et al.
Diagnostics (basel, Switzerland), 2021
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs).
Incorvaia L et al.
Therapeutic Advances in Medical Oncology, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
Smrke A et al.
Future Oncology (london, England), 2020
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Familial PDGFRA-mutation syndrome: somatic and gastrointestinal phenotype.
Manley PN et al.
Human Pathology, 2018
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
Molecular characterization and pathogenesis of gastrointestinal stromal tumor.
Niinuma T et al.
Translational Gastroenterology and Hepatology, 2018
Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
Chen Q et al.
Oncotargets and Therapy, 2018
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I et al.
Oncotarget, 2017
Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies.
Hedenström P et al.
World Journal of Gastroenterology, 2017
Familial Gastrointestinal Stromal Tumor with Germline KIT Mutations Accompanying Hereditary Breast and Ovarian Cancer Syndrome.
Sekido Y et al.
Anticancer Research, 2017
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M et al.
Oncotarget, 2016
Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.
Xu N et al.
Oncotarget, 2016
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
PDGFRA-mutant syndrome.
Ricci R et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2015
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
MacConaill LE et al.
The Journal of Molecular Diagnostics : Jmd, 2014
Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma.
Jiang N et al.
Oncology Reports, 2014
Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
Bar J et al.
Clinical Lung Cancer, 2014
High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H et al.
Human Pathology, 2014
Chromosomal aberrations in primary PDGFRA-mutated gastrointestinal stromal tumors.
Schaefer IM et al.
Human Pathology, 2014
Oncogene mutational profile in nasopharyngeal carcinoma.
Zhang ZC et al.
Oncotargets and Therapy, 2014
High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer.
Kim S et al.
Plos One, 2014
Value of epithelioid morphology and PDGFRA immunostaining pattern for prediction of PDGFRA mutated genotype in gastrointestinal stromal tumors (GISTs).
Agaimy A et al.
International Journal of Clinical and Experimental Pathology, 2013
Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin.
Zanaruddin SN et al.
Plos One, 2013
Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications.
Postow MA et al.
Clinical Sarcoma Research, 2012
Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Heinrich MC et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.
Pommier SJ et al.
Annals of Surgical Oncology, 2012
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.
Elling C et al.
Blood, 2011
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
Deshpande V et al.
Bmc Cancer, 2011
Multiple non-metastatic gastrointestinal stromal tumors. Differential features.
Díaz-Delgado M et al.
Revista Espanola De Enfermedades Digestivas, 2010
Hereditary gastrointestinal stromal tumors sharing the KIT Exon 17 germline mutation p.Asp820Tyr develop through different cytogenetic progression pathways.
Veiga I et al.
Genes, Chromosomes & Cancer, 2010
Profiling critical cancer gene mutations in clinical tumor samples.
MacConaill LE et al.
Plos One, 2009
Kinase domain mutations in cancer: implications for small molecule drug design strategies.
Bikker JA et al.
Journal of Medicinal Chemistry, 2009